A recent study revealed that BRG1 may be a mediator of PF and MCL targeting the asparagine (N1540) residue of BRG1 may be a new therapeutic strategy for PF (Li et al., 2023b). The gene discussed is SMARCA4; the disease is mantle cell lymphoma.